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PREAMBLE
The medical profession should play a central role in
evaluating the evidence related to drugs, devices, and
procedures for the detection, management, and preven-
tion of disease. When properly applied, expert analysis of
available data on the beneﬁts and risks of these therapies
and procedures can improve the quality of care, optimize
patient outcomes, and favorably affect costs by focusing
resources on the most effective strategies. An organized
and directed approach to a thorough review of evidence
has resulted in the production of clinical practice guide-
lines that assist clinicians in selecting the best manage-
ment strategy for an individual patient. Moreover, clinical
practice guidelines can provide a foundation for other
applications, such as performance measures, appropriate
use criteria, and both quality improvement and clinical
decision support tools.
The American College of Cardiology (ACC) and the
American Heart Association (AHA) have jointly engaged in
the production of guidelines in the area of cardiovascular
disease since 1980. The ACC/AHA Task Force on Practice
Guidelines (Task Force), whose charge is to develop,
update, or revise practice guidelines for cardiovascular
diseases and procedures, directs this effort. Writing
committees are charged with the task of performing an
assessment of the evidence and acting as an independent
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2248group of authors to develop, update, or revise written
recommendations for clinical practice.
Experts in the subject under consideration are selected
from both organizations to examine subject-speciﬁc data
and write guidelines. Writing committees are speciﬁcally
charged to perform a literature review; weigh the strength
of evidence for or against particular tests, treatments, or
procedures; and include estimates of expected health
outcomes where such data exist. Patient-speciﬁc modi-
ﬁers, comorbidities, and issues of patient preference
that may inﬂuence the choice of tests or therapies are
considered, as well as frequency of follow-up and cost-
effectiveness. When available, information from studies
on cost is considered; however, review of data on efﬁcacy
and outcomes constitutes the primary basis for preparing
recommendations in this guideline.
In analyzing the data, and developing recommenda-
tions and supporting text, the writing committee uses
evidence-based methodologies developed by the Task
Force (1). The Classiﬁcation of Recommendation (COR) is
an estimate of the size of the treatment effect, with
consideration given to risks versus beneﬁts, as well as
evidence and/or agreement that a given treatment or
procedure is or is not useful/effective or in some situa-
tions may cause harm; this is deﬁned in Table 1. The Level
of Evidence (LOE) is an estimate of the certainty or
precision of the treatment effect. The writing committee
reviews and ranks evidence supporting each recommenda-
tion, with the weight of evidence ranked as LOE A, B, or C,
according to speciﬁc deﬁnitions that are included in
Table 1. Studies are identiﬁed as observational, retro-
spective, prospective, or randomized, as appropriate. For
certain conditions for which inadequate data are avail-
able, recommendations are based on expert consensus
and clinical experience and are ranked as LOE C. When
recommendations at LOE C are supported by historical
clinical data, appropriate references (including clinical
reviews) are cited if available.
For issues with sparse available data, a survey of cur-
rent practice among the clinician members of the writing
committee is the basis for LOE C recommendations and no
references are cited.
The schema for COR and LOE is summarized in Table 1,
which also provides suggested phrases for writing rec-
ommendations within each COR.
A new addition to this methodology is the separation of
the Class III recommendations to delineate whether the
recommendation is determined to be of “no beneﬁt” or is
associated with “harm” to the patient. In addition, in view
of the increasing number of comparative effectiveness
studies, comparator verbs and suggested phrases for
writing recommendations for the comparative effective-
ness of one treatment or strategy versus another are
included for COR I and IIa, LOE A or B only.In view of the advances in medical therapy across
the spectrum of cardiovascular diseases, the Task
Force has designated the term guideline-directed medical
therapy to represent optimal medical therapy as deﬁned
by ACC/AHA guideline (primarily Class I)–recommended
therapies. This new term, guideline-directed medical ther-
apy, is used herein and throughout subsequent guidelines.
Therapies not available in the United States are dis-
cussed in the text without a speciﬁc COR. For studies
performed in large numbers of subjects outside North
America, each writing committee reviews the potential
impact of different practice patterns and patient pop-
ulations on the treatment effect and relevance to the ACC/
AHA target population to determine whether the ﬁndings
should inform a speciﬁc recommendation.
The ACC/AHA practice guidelines are intended to assist
clinicians in clinical decision making by describing a
range of generally acceptable approaches to the diagnosis,
management, and prevention of speciﬁc diseases or con-
ditions. The guidelines attempt to deﬁne practices that
meet the needs of most patients in most circumstances.
The ultimate judgment about care of a particular patient
must be made by the clinician and patient in light of
all the circumstances presented by that patient. As a
result, situations may arise in which deviations from
these guidelines may be appropriate. Clinical decision
making should involve consideration of the quality and
availability of expertise in the area where care is pro-
vided. When these guidelines are used as the basis for
regulatory or payer decisions, the goal should be
improvement in quality of care. The Task Force recog-
nizes that situations arise in which additional data are
needed to inform patient care more effectively; these
areas are identiﬁed within each respective guideline
when appropriate.
Prescribed courses of treatment in accordance with
these recommendations are effective only if followed.
Because lack of patient understanding and adherence
may adversely affect outcomes, clinicians should make
every effort to engage the patient’s active participation in
prescribed medical regimens and lifestyles. In addition,
patients should be informed of the risks, beneﬁts, and
alternatives to a particular treatment and should be
involved in shared decision making whenever feasible,
particularly for COR IIa and IIb, for which the beneﬁt-to-
risk ratio may be lower.
The Task Force makes every effort to avoid actual,
potential, or perceived conﬂicts of interest that may arise
as a result of relationships with industry and other en-
tities (RWI) among the members of the writing commit-
tee. All writing committee members and peer reviewers of
the guideline are required to disclose all current
healthcare-related relationships, including those existing
12 months before initiation of the writing effort.
TABLE 1 Applying Classiﬁcation of Recommendations and Level of Evidence
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend
themselves to clinical trials. Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.
*Data available from clinical trials or registries about the usefulness/efﬁcacy in different subpopulations, such as sex, age, history of diabetes mellitus, history of prior myocardial
infarction, history of heart failure, and prior aspirin use.
†For comparative-effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons
of the treatments or strategies being evaluated.
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2249In December 2009, the ACC and AHA implemented a
new RWI policy that requires the writing committee
chair plus a minimum of 50% of the writing committee
to have no relevant RWI (Appendix 1 includes the ACC/
AHA deﬁnition of relevance). The Task Force and all
writing committee members review their respective
RWI disclosures during each conference call and/or
meeting of the writing committee, and members provide
updates to their RWI as changes occur. All guideline
recommendations require a conﬁdential vote by the
writing committee and require approval by a consensus
of the voting members. Members may not draft or vote
on any recommendations pertaining to their RWI. Mem-
bers who recused themselves from voting are indicatedin the list of writing committee members, and speciﬁc
section recusals are noted in Appendix 1. Authors’ and
peer reviewers’ RWI pertinent to this guideline are dis-
closed in Appendices 1 and 2. In addition, to ensure
complete transparency, writing committee members’
comprehensive disclosure information—including RWI
not pertinent to this document—is available as an online
supplement. Comprehensive disclosure information for
the Task Force is also available as an Online Supplement.
The ACC and AHA exclusively sponsor the work of the
writing committee, without commercial support. Writing
committee members volunteered their time for this
activity. Guidelines are ofﬁcial policy of both the ACC
and AHA.
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2250In an effort to maintain relevance at the point of care
for clinicians, the Task Force continues to oversee an
ongoing process improvement initiative. As a result, in
response to pilot projects, several changes to this guide-
line will be apparent, including limited narrative text, a
focus on summary and evidence tables (with references
linked to abstracts in PubMed), and more liberal use of
summary recommendation tables (with references that
support the LOE) to serve as a quick reference.
InApril 2011, the Institute ofMedicine released 2 reports:
Finding What Works in Health Care: Standards for Sys-
tematic Reviews and Clinical Practice Guidelines We Can
Trust (2,3). It is noteworthy that the Institute of Medicine
cited ACC/AHA practice guidelines as being compliant
with many of the proposed standards. A thorough review
of these reports and of our current methodology is under
way, with further enhancements anticipated.
The recommendations in this guideline are considered
current until they are superseded by a focused update,
the full-text guideline is revised, or until a published
addendum declares it out of date and no longer ofﬁcial
ACC/AHA policy. The reader is encouraged to consult the
full-text guideline (4) for additional guidance and details
about atrial ﬁbrillation (AF), because the executive sum-
mary contains mainly the recommendations.
Jeffrey L. Anderson, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines
1. INTRODUCTION
1.1. Methodology and Evidence Review
The recommendations listed in this document are,
whenever possible, evidence based. An extensive evi-
dence review was conducted, focusing on 2006 through
October 2012 and selected other references through March
2014. The relevant data are included in evidence tables in
the Online Data Supplement. Searches were extended
to studies, reviews, and other evidence conducted in
human subjects, published in English, and accessible
through PubMed, EMBASE, Cochrane, Agency for Health-
care Research and Quality Reports, and other selected da-
tabases relevant to this guideline. Key search words
included but were not limited to the following: age,
antiarrhythmic, atrial ﬁbrillation, atrial remodeling, atrio-
ventricular conduction, atrioventricular node, cardiover-
sion, classiﬁcation, clinical trial, complications, concealed
conduction, cost-effectiveness, deﬁbrillator, demographics,
epidemiology, experimental, heart failure, hemodynamics,
human, hyperthyroidism, hypothyroidism, meta-analysis,
myocardial infarction, pharmacology, postoperative, preg-
nancy, pulmonary disease, quality of life, rate control,
rhythm control, risks, sinus rhythm, symptoms, and
tachycardia-mediated cardiomyopathy. Additionally, the
writing committee reviewed documents related to AFpreviously published by the ACC and AHA. References
selected andpublished in this document are representative
and not all-inclusive.
1.2. Organization of the Writing Committee
The 2014 AF writing committee was composed of clini-
cians with broad expertise related to AF and its treatment,
including adult cardiology, electrophysiology, cardiotho-
racic surgery, and heart failure (HF). The writing com-
mittee was assisted by staff from the ACC and AHA. Under
the guidance of the Task Force, the Heart Rhythm Society
was invited to be a partner organization and provided
representation. The writing committee also included a
representative from the Society of Thoracic Surgeons. The
rigorous methodological policies and procedures noted in
the Preamble differentiate ACC/AHA guidelines from
other published guidelines and statements.
1.3. Document Review and Approval
This document was reviewed by 2 ofﬁcial reviewers each
nominated by the ACC, AHA, and Heart Rhythm Society,
as well as 1 reviewer from the Society of Thoracic Sur-
geons and 43 individual content reviewers (from the ACC
Electrophysiology Section Leadership Council, ACC Adult
Congenital and Pediatric Cardiology Section Leadership
Council, ACC Association of International Governors, ACC
Heart Failure and Transplant Section Leadership Council,
ACC Imaging Section Leadership Council, ACC Interven-
tional Section Leadership Council, ACC Surgeons’ Coun-
cil, and the Heart Rhythm Society Scientiﬁc Documents
Committee). All information on reviewers’ RWI was
distributed to the writing committee and is published in
this document (Appendix 2).
This document was approved for publication by the
governing bodies of the ACC, AHA, and Heart Rhythm
Society and endorsed by the Society of Thoracic Surgeons.
1.4. Scope of the Guideline
The task of the 2014 writing committee was to establish
revised guidelines for optimum management of AF. The
new guideline incorporates new and existing knowledge
derived from published clinical trials, basic science, and
comprehensive review articles, along with evolving
treatment strategies and new drugs. This guideline
supersedes the “ACC/AHA/ESC 2006 Guidelines for the
Management of Patients With Atrial Fibrillation” (5) and
the 2 subsequent focused updates from 2011 (6,7). In
addition, the ACC, AHA, American College of Physicians,
and American Academy of Family Physicians submitted a
proposal to the Agency for Healthcare Research and
Quality to perform a systematic review on speciﬁc ques-
tions related to the treatment of AF. The data from that
report were reviewed by the writing committee and
incorporated where appropriate (8a,8b).
*CHA2DS2-VASc indicates Congestive heart failure, Hypertension, Age $75
years (doubled), Diabetes mellitus, prior Stroke or TIA or thromboembolism
(doubled), Vascular disease, Age 65 to 74 years, Sex category.
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2251The 2014 AF guideline is organized thematically, with
recommendations, where appropriate, provided with
each section. Some recommendations from earlier
guidelines have been eliminated or updated as warranted
by new evidence or a better understanding of earlier
evidence. In developing the 2014 AF guideline, the
writing committee reviewed prior published guidelines
and related statements. Table 2 lists these publications
and statements deemed pertinent to this effort and is
intended for use as a resource.
2. CLINICAL CHARACTERISTICS AND
EVALUATION OF AF
2.1. AF Classiﬁcation
AF may be described in terms of the duration of episodes
using a simpliﬁed scheme shown in Table 3 (5,29,30).
Implanted loop recorders, pacemakers, and deﬁbrillators
offer the possibility of reporting frequency, rate, and dura-
tion of abnormal atrial rhythms, including AF (31,32). Epi-
sodes often increase in frequency and duration over time.
2.2. Mechanisms of AF and Pathophysiology
AF occurs when structural and/or electrophysiological
abnormalities alter atrial tissue to promote abnormal
impulse formation and/or propagation (Figure 1). These
abnormalities are caused by diverse pathophysiological
mechanisms (29,33,34), such that AF represents a ﬁnal
common phenotype for multiple disease pathways and
mechanisms that are incompletely understood.
2.3. Risk Factors and Associated Heart Disease
Multiple clinical risk factors, electrocardiographic and
echocardiographic features, and biochemical markers are
associated with an increased risk of AF (Table 4).
2.4. Clinical Evaluation: Recommendation
See Appendix 3 for information on initial clinical evalua-
tion in patients with AF.
CLASS I
1. Electrocardiographic documentation is recommended to
establish the diagnosis of AF. (Level of Evidence: C)
3. THROMBOEMBOLIC RISK AND TREATMENT
3.1. Risk-Based Antithrombotic Therapy: Recommendations
See Table 5 for a summary of recommendations from this
section.
CLASS I
1. In patients with AF, antithrombotic therapy should be individ-
ualized based on shared decision making after discussion of the
absolute and relative risks of stroke and bleeding and the
patient’s values and preferences. (Level of Evidence: C)2. Selection of antithrombotic therapy should be based on the
risk of thromboembolism irrespective of whether the AF
pattern is paroxysmal, persistent, or permanent (64–67).
(Level of Evidence: B)
3. In patients with nonvalvular AF, the CHA2DS2-VASc* score
is recommended for assessment of stroke risk (68–70).
(Level of Evidence: B)
4. For patients with AF who have mechanical heart valves,
warfarin is recommended, and the target international
normalized ratio (INR) intensity (2.0 to 3.0 or 2.5 to 3.5)
should be based on the type and location of the prosthesis
(71–73). (Level of Evidence: B)
5. For patients with nonvalvular AF with prior stroke, transient
ischemic attack (TIA), or a CHA2DS2-VASc score of 2 or greater,
oral anticoagulants are recommended. Options include warfarin
(INR 2.0 to 3.0) (68–70) (Level of Evidence: A), dabigatran (74)
(Level of Evidence: B), rivaroxaban (75) (Level of Evidence: B), or
apixaban (76). (Level of Evidence: B)
6. Among patients treated with warfarin, the INR should be
determined at least weekly during initiation of antith-
rombotic therapy and at least monthly when anticoagula-
tion (INR in range) is stable (77–79). (Level of Evidence: A)
7. For patients with nonvalvular AF unable to maintain a
therapeutic INR level with warfarin, use of a direct
thrombin or factor Xa inhibitor (dabigatran, rivaroxaban, or
apixaban) is recommended. (Level of Evidence: C)
8. Reevaluation of the need for and choice of antithrombotic
therapy at periodic intervals is recommended to reassess
stroke and bleeding risks. (Level of Evidence: C)
9. Bridging therapy with unfractionated heparin or low-molecular-
weight heparin (LMWH) is recommended for patients with AF
andamechanical heart valveundergoingprocedures that require
interruption of warfarin. Decisions on bridging therapy should
balance the risks of stroke and bleeding. (Level of Evidence: C)
10. For patients with AF without mechanical heart valves who
require interruption of warfarin or new anticoagulants for
procedures, decisions about bridging therapy (LMWH or
unfractionated heparin) should balance the risks of stroke
and bleeding and the duration of time a patient will not be
anticoagulated. (Level of Evidence: C)
11. Renal function should be evaluated before initiation of
direct thrombin or factor Xa inhibitors and should be
reevaluated when clinically indicated and at least annually
(80–82). (Level of Evidence: B)
12. For patients with atrial ﬂutter, antithrombotic therapy is
recommended according to the same risk proﬁle used for
AF. (Level of Evidence: C)
TABLE 2 Associated Guidelines and Statements
Title Organization Publication Year/Reference
Guidelines
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure (JNC 7)
NHLBI 2003 (9)
Assessment of Cardiovascular Risk in Asymptomatic Adults ACC/AHA 2010 (10)
Coronary Artery Bypass Graft Surgery ACC/AHA 2011 (11)
Hypertrophic Cardiomyopathy ACC/AHA 2011 (12)
Percutaneous Coronary Intervention ACC/AHA/SCAI 2011 (13)
Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and
Other Atherosclerotic Vascular Disease
AHA/ACC 2011 (14)
Atrial Fibrillation* CCS 2012 (15)
Atrial Fibrillation ESC 2012 (16)
Stable Ischemic Heart Disease ACC/AHA/ACP/AATS/PCNA/SCAI/STS 2012 (17)
Antithrombotic Therapy ACCP 2012 (18)
Device-Based Therapy ACC/AHA/HRS 2012 (19)
Heart Failure ACC/AHA 2013 (20)
ST-Elevation Myocardial Infarction ACC/AHA 2013 (21)
Unstable Angina/Non-ST-Elevation Myocardial Infarction ACC/AHA 2014 (22)
Valvular Heart Disease AHA/ACC 2014 (23)
Assessment of Cardiovascular Risk ACC/AHA 2013 (24)
Lifestyle Management to Reduce Cardiovascular Risk AHA/ACC 2013 (25)
Management of Overweight and Obesity in Adults AHA/ACC/TOS 2013 (26)
Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults ACC/AHA 2013 (27)
Statements
Treatment of Atrial Fibrillation AHRQ 2013 (8a,8b)
Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular
Atrial Fibrillation: A Science Advisory for Healthcare Professionals
AHA/ASA 2012 (28)
Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation:
Recommendations for Patient Selection, Procedural Techniques, Patient
Management and Follow-Up, Deﬁnitions, Endpoints, and Research Trial Design
HRS/EHRA/ECAS 2012 (29)
*Includes the following sections: Catheter Ablation for AF/Atrial Flutter; Prevention and Treatment of AF Following Cardiac Surgery; Rate and Rhythm Management; Prevention of
Stroke and Systemic Thromboembolism in AF and Flutter; Management of Recent-Onset AF and Flutter in the Emergency Department; Surgical Therapy; The Use of Antiplatelet
Therapy in the Outpatient Setting; and Focused 2012 Update of the CCS AF Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control.
AATS indicates American Association for Thoracic Surgery; ACC, American College of Cardiology; ACCP, American College of Chest Physicians; ACP, American College of Physicians;
AF, atrial ﬁbrillation; AHA, American Heart Association; AHRQ, Agency for Healthcare Research and Quality; ASA, American Stroke Association; CCS, Canadian Cardiology Society; ECAS,
European Cardiac Arrhythmia Society; EHRA, European Heart Rhythm Association; ESC, European Society of Cardiology; HRS, Heart Rhythm Society; JNC, Joint National Committee;
NHLBI, National Heart, Lung, and Blood Institute; PCNA, Preventive Cardiovascular Nurses Association; SCAI, Society for Cardiovascular Angiography and Interventions; STS, Society of
Thoracic Surgeons; and TOS, The Obesity Society.
ySee the 2011 percutaneous coronary intervention guideline for type of stent
and duration of dual antiplatelet therapy recommendations (13).
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2252CLASS IIa
1. For patients with nonvalvular AF and a CHA2DS2-VASc score
of 0, it is reasonable to omit antithrombotic therapy (80,81).
(Level of Evidence: B)
2. For patients with nonvalvular AF with a CHA2DS2-VASc score
of 2 or greater and who have end-stage chronic kidney
disease (CKD) (creatinine clearance <15 mL/min) or are on
hemodialysis, it is reasonable to prescribe warfarin (INR 2.0
to 3.0) for oral anticoagulation (82). (Level of Evidence: B)
CLASS IIb
1. For patients with nonvalvular AF and a CHA2DS2-VASc score
of 1, no antithrombotic therapy or treatment with an oral
anticoagulant or aspirin may be considered. (Level of Evi-
dence: C)2. For patients with nonvalvular AF and moderate-to-severe
CKD with CHA2DS2-VASc scores of 2 or greater, treatment
with reduced doses of direct thrombin or factor Xa inhibitors
may be considered (e.g., dabigatran, rivaroxaban, or apix-
aban), but safety and efﬁcacy have not been established.
(Level of Evidence: C)
3. In patients with AF undergoing percutaneous coronary
intervention,y bare-metal stents may be considered to
minimize the required duration of dual antiplatelet therapy.
Anticoagulation may be interrupted at the time of the
TABLE 3 Deﬁnitions of AF: A Simpliﬁed Scheme
Term Deﬁnition
Paroxysmal AF  AF that terminates spontaneously or with intervention within 7 d of onset.
 Episodes may recur with variable frequency.
Persistent AF  Continuous AF that is sustained >7 d.
Long-standing persistent AF  Continuous AF >12 mo in duration.
Permanent AF  The term “permanent AF” is used when the patient and clinician make a joint decision to stop further attempts
to restore and/or maintain sinus rhythm.
 Acceptance of AF represents a therapeutic attitude on the part of the patient and clinician rather than an inherent
pathophysiological attribute of AF.
 Acceptance of AF may change as symptoms, efﬁcacy of therapeutic interventions, and patient and clinician preferences evolve.
Nonvalvular AF  AF in the absence of rheumatic mitral stenosis, a mechanical or bioprosthetic heart valve, or mitral valve repair.
AF indicates atrial ﬁbrillation.
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2253procedure to reduce the risk of bleeding at the site of pe-
ripheral arterial puncture. (Level of Evidence: C)
4. Following coronary revascularization (percutaneous or sur-
gical) in patients with AF and a CHA2DS2-VASc score of 2 or
greater, it may be reasonable to use clopidogrel (75 mg once
daily) concurrently with oral anticoagulants but without
aspirin (83). (Level of Evidence: B)
CLASS III: NO BENEFIT
1. The direct thrombin inhibitor dabigatran and the factor
Xa inhibitor rivaroxaban are not recommended in patients
with AF and end-stage CKD or on dialysis because of the lackFIGURE 1 Mechanisms of AF
AF indicates atrial ﬁbrillation; Caþþ, ionized calcium; and RAAS, renin-angiotensof evidence from clinical trials regarding the balance of risks
and beneﬁts (74–76,84–86). (Level of Evidence: C)
CLASS III: HARM
1. The direct thrombin inhibitor dabigatran should not be used
in patients with AF and a mechanical heart valve (87). (Level
of Evidence: B)
3.2. Risk Stratiﬁcation Schemes (CHADS2 and CHA2DS2-VASc)
One meta-analysis has stratiﬁed ischemic stroke risk
among patients with nonvalvular AF using the following
scoring systems: AF Investigators (88), CHADS2 (Congestivein-aldosterone system.
TABLE 4 Selected Risk Factors and Biomarkers for AF
Clinical Risk Factors References
Increasing age (35)
Hypertension (35)
Diabetes mellitus (35)
MI (35)
VHD (35)
HF (35,36)
Obesity (37–39)
Obstructive sleep apnea (39)
Cardiothoracic surgery (40)
Smoking (41)
Exercise (42–44)
Alcohol use (45–47)
Hyperthyroidism (48–50)
Increased pulse pressure (51)
European ancestry (52)
Family history (53)
Genetic variants (54–57)
ECG
LVH (58)
Echocardiographic
LA enlargement (58,59)
Decreased LV fractional shortening (58)
Increased LV wall thickness (58)
Biomarkers
Increased CRP (60,61)
Increased BNP (62,63)
AF indicates atrial ﬁbrillation; BNP, B-type natriuretic peptide; CRP, C-reactive protein;
ECG, electrocardiographic; HF, heart failure; LA, left atrial; LV, left ventricular; LVH, left
ventricular hypertrophy; MI, myocardial infarction; and VHD, valvular heart disease.
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2254heart failure, Hypertension, Age$75 years, Diabetes mellitus,
Prior Stroke or TIA or Thromboembolism [doubled]) (89),
or CHA2DS2-VASc (Congestive heart failure, Hypertension,
Age$75 years [doubled], Diabetesmellitus, Prior Stroke or TIA
or thromboembolism [doubled], Vascular disease, Age 65 to 74
years, Sex category) (Table 6).
3.3. Considerations in Selecting Anticoagulants
For patients with CKD, dose modiﬁcations of the new
agents are available (Table 7); however, for those with
severe or end-stage CKD, warfarin remains the anticoag-
ulant of choice, as there are no or very limited data for
these patients. Among patients on hemodialysis, warfarin
has been used with acceptable risks of hemorrhage (82).
3.4. Cardiac Surgery—Left Atrial Appendage Occlusion/Excision:
Recommendation
CLASS IIb
1. Surgical excision of the left atrial appendage may be
considered in patients undergoing cardiac surgery. (Level of
Evidence: C)4. RATE CONTROL: RECOMMENDATIONS
See Table 8 for a summary of recommendations for this
section and Table 9 for common medication dosages for
rate control of AF.
CLASS I
1. Control of the ventricular rate using a beta blocker or non-
dihydropyridine calcium channel antagonist is recommended
for patients with paroxysmal, persistent, or permanent AF
(93–95). (Level of Evidence: B)
2. Intravenous administration of a beta blocker or nondi-
hydropyridine calcium channel blocker is recommended to slow
the ventricular heart rate in the acute setting in patients without
pre-excitation. In hemodynamically unstable patients, electrical
cardioversion is indicated (96–99). (Level of Evidence: B)
3. In patients who experience AF-related symptoms during
activity, the adequacy of heart rate control should be
assessed during exertion, adjusting pharmacological treat-
ment as necessary to keep the ventricular rate within the
physiological range. (Level of Evidence: C)
CLASS IIa
1. A heart rate control (resting heart rate <80 beats per minute
[bpm]) strategy is reasonable for symptomatic management
of AF (95,100). (Level of Evidence: B)
2. Intravenous amiodarone can be useful for rate control in critically
ill patients without pre-excitation (101–103). (Level of Evidence: B)
3. Atrioventricular (AV) nodal ablation with permanent ven-
tricular pacing is reasonable to control heart rate when
pharmacological therapy is inadequate and rhythm control is
not achievable (104–106). (Level of Evidence: B)
CLASS IIb
1. A lenient rate-control strategy (resting heart rate <110 bpm)
may be reasonable as long as patients remain asymptomatic
and left ventricular systolic function is preserved (100).
(Level of Evidence: B)
2. Oral amiodarone may be useful for ventricular rate control
when other measures are unsuccessful or contraindicated.
(Level of Evidence: C)
CLASS III: HARM
1. AV nodal ablation with permanent ventricular pacing should not
be performed to improve rate control without prior attempts to
achieve rate control with medications. (Level of Evidence: C)
2. Nondihydropyridine calcium channel antagonists should not
be used in patients with decompensated HF as these may lead
to further hemodynamic compromise. (Level of Evidence: C)
3. In patients with pre-excitation and AF, digoxin, non-
dihydropyridine calcium channel antagonists, or intravenous
amiodarone should not be administered as they may increase
the ventricular response and may result in ventricular
ﬁbrillation (107). (Level of Evidence: B)
TABLE 5 Summary of Recommendations for Risk-Based Antithrombotic Therapy
Recommendations COR LOE References
Antithrombotic therapy based on shared decision making, discussion of risks of stroke and bleeding,
and patient’s preferences
I C N/A
Selection of antithrombotic therapy based on risk of thromboembolism I B (64–67)
CHA2DS2-VASc score recommended to assess stroke risk I B (68–70)
Warfarin recommended for mechanical heart valves and target INR intensity based on type and
location of prosthesis
I B (71–73)
With prior stroke, TIA, or CHA2DS2-VASc score $2, oral anticoagulants recommended. Options include:
Warfarin I A (68–70)
Dabigatran, rivaroxaban, or apixaban I B (74–76)
With warfarin, determine INR at least weekly during initiation of therapy and monthly when stable I A (77–79)
Direct thrombin or factor Xa inhibitor recommended if unable to maintain therapeutic INR I C N/A
Reevaluate the need for anticoagulation at periodic intervals I C N/A
Bridging therapy with UFH or LMWH recommended with a mechanical heart valve if warfarin is
interrupted. Bridging therapy should balance risks of stroke and bleeding
I C N/A
For patients without mechanical heart valves, bridging therapy decisions should balance stroke and
bleeding risks against duration of time patient will not be anticoagulated
I C N/A
Evaluate renal function before initiation of direct thrombin or factor Xa inhibitors, and reevaluate
when clinically indicated and at least annually
I B (80–82)
For atrial ﬂutter, antithrombotic therapy is recommended as for AF I C N/A
With nonvalvular AF and CHA2DS2-VASc score of 0, it is reasonable to omit antithrombotic therapy IIa B (80,81)
With CHA2DS2-VASc score $2 and end-stage CKD (CrCl <15 mL/min) or on hemodialysis,
it is reasonable to prescribe warfarin for oral anticoagulation
IIa B (82)
With nonvalvular AF and a CHA2DS2-VASc score of 1, no antithrombotic therapy or treatment
with oral anticoagulant or aspirin may be considered
IIb C N/A
With moderate-to-severe CKD and CHA2DS2-VASc scores $2, reduced doses of direct thrombin
or factor Xa inhibitors may be considered
IIb C N/A
For PCI,* BMS may be considered to minimize duration of DAPT IIb C N/A
After coronary revascularization in patients with CHA2DS2-VASc score $2, it may be reasonable
to use clopidogrel concurrently with oral anticoagulants but without aspirin
IIb B (83)
Direct thrombin dabigatran and factor Xa inhibitor rivaroxaban are not recommended in patients
with AF and end-stage CKD or on dialysis because of a lack of evidence from clinical trials
regarding the balance of risks and beneﬁts
III: No Beneﬁt C (74–76,84–86)
Direct thrombin inhibitor dabigatran should not be used with a mechanical heart valve III: Harm B (87)
*See the 2011 PCI guideline for type of stent and duration of DAPT recommendations (13).
AF indicates atrial ﬁbrillation; BMS, bare-metal stent; CHA2DS2-VASc, Congestive heart failure, Hypertension, Age $75 years (doubled), Diabetes mellitus, Prior Stroke or TIA or
thromboembolism (doubled), Vascular disease, Age 65 to 74 years, Sex category; CKD, chronic kidney disease; COR, Class of Recommendation; CrCl, creatinine clearance; DAPT, dual
antiplatelet therapy; INR, international normalized ratio; LMWH, low-molecular-weight heparin; LOE, Level of Evidence; N/A, not applicable; PCI, percutaneous coronary intervention;
TIA, transient ischemic attack; and UFH, unfractionated heparin.
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22554. Dronedarone should not be used to control the ventricular
rate in patients with permanent AF as it increases the risk of
the combined endpoint of stroke, myocardial infarction,
systemic embolism, or cardiovascular death (108,109).
(Level of Evidence: B)
5. RHYTHM CONTROL: RECOMMENDATIONS
See Table 10 for a summary of recommendations for
rhythm control.
5.1. Prevention of Thromboembolism
CLASS I
1. For patients with AF or atrial ﬂutter of 48 hours’ duration
or longer, or when the duration of AF is unknown,anticoagulation with warfarin (INR 2.0 to 3.0) is recom-
mended for at least 3 weeks before and 4 weeks after car-
dioversion, regardless of the CHA2DS2-VASc score and the
method (electrical or pharmacological) used to restore sinus
rhythm (110–113). (Level of Evidence: B)
2. For patients with AF or atrial ﬂutter of more than 48 hours’
duration or unknown duration that requires immediate car-
dioversion for hemodynamic instability, anticoagulation
should be initiated as soon as possible and continued for at
least 4 weeks after cardioversion unless contraindicated.
(Level of Evidence: C)
3. For patients with AF or atrial ﬂutter of less than 48 hours’
duration and with high risk of stroke, intravenous heparin or
LMWH, or administration of a factor Xa or direct thrombin
inhibitor, is recommended as soon as possible before or
TABLE 6
Comparison of the CHADS2 and CHA2DS2-VASc
Risk Stratiﬁcation Scores for Subjects With
Nonvalvular AF
Deﬁnition and Scores for
CHADS2 and CHA2DS2-VASc
Stroke Risk Stratiﬁcation With
the CHADS2 and CHA2DS2-VASc
Scores
Score
Adjusted Stroke
Rate (% per y)
CHADS2 CHADS2*
Congestive HF 1 0 1.9
Hypertension 1 1 2.8
Age $75 y 1 2 4.0
Diabetes mellitus 1 3 5.9
Stroke/TIA/TE 2 4 8.5
Maximum score 6 5 12.5
6 18.2
CHA2DS2-VASc CHA2DS2-VASc†
Congestive HF 1 0 0
Hypertension 1 1 1.3
Age $75 y 2 2 2.2
Diabetes mellitus 1 3 3.2
Stroke/TIA/TE 2 4 4.0
Vascular disease (prior MI, PAD,
or aortic plaque)
1 5 6.7
Age 65–74 y 1 6 9.8
Sex category (i.e., female sex) 1 7 9.6
Maximum score 9 8 6.7
9 15.20
*These adjusted stroke rates are based on data for hospitalized patients with AF and
were published in 2001 (89). Because stroke rates are decreasing, actual stroke rates in
contemporary nonhospitalized cohorts might vary from these estimates.
†Adjusted stroke rate scores are based on data from Lip and colleagues
(16,30,68,90,91). Actual rates of stroke in contemporary cohorts might vary from these
estimates.
AF indicates atrial ﬁbrillation; CHADS2, Congestive heart failure, Hypertension, Age
$75 years, Diabetes mellitus, Prior Stroke or TIA or Thromboembolism (doubled);
CHA2DS2-VASc, Congestive heart failure, Hypertension, Age $75 years (doubled),
Diabetes mellitus, Prior Stroke or TIA or thromboembolism (doubled), Vascular disease,
Age 65–74 years, Sex category; HF, heart failure; MI, myocardial infarction; PAD,
peripheral artery disease; TE, thromboembolism; and TIA, transient ischemic attack
(90,91).
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2256immediately after cardioversion, followed by long-term
anticoagulation therapy. (Level of Evidence: C)
4. Following cardioversion for AF of any duration, the decision
about long-term anticoagulation therapy should be based on the
thromboembolic risk proﬁle (Section 3). (Level of Evidence: C)
CLASS IIa
1. For patients with AF or atrial ﬂutter of 48 hours’ duration or
longer or of unknown duration who have not been anti-
coagulated for the preceding 3 weeks, it is reasonable to
perform transesophageal echocardiography before cardio-
version and proceed with cardioversion if no left atrial
thrombus is identiﬁed, including in the left atrial appen-
dage, provided that anticoagulation is achieved beforetransesophageal echocardiography and maintained after
cardioversion for at least 4 weeks (114). (Level of Evidence: B)
2. For patients with AF or atrial ﬂutter of 48 hours’ duration or
longer or when duration of AF is unknown, anticoagulation
with dabigatran, rivaroxaban, or apixaban is reasonable for
at least 3 weeks before and 4 weeks after cardioversion
(115–117). (Level of Evidence: C)
CLASS IIb
1. For patients with AF or atrial ﬂutter of less than 48 hours’
duration who are at low thromboembolic risk, anticoagulation
(intravenous heparin, LMWH, or a new oral anticoagulant) or
no antithrombotic therapy may be considered for cardiover-
sion, without the need for postcardioversion oral anti-
coagulation (118). (Level of Evidence: C)
5.2. Direct-Current Cardioversion
CLASS I
1. In pursuing a rhythm-control strategy, cardioversion is rec-
ommended for patients with AF or atrial ﬂutter as a method
to restore sinus rhythm. If cardioversion is unsuccessful,
repeated attempts at direct-current cardioversion may be
made after adjusting the location of the electrodes, applying
pressure over the electrodes or following administration of
an antiarrhythmic medication (119). (Level of Evidence: B)
2. Cardioversion is recommended when a rapid ventricular
response to AF or atrial ﬂutter does not respond promptly
to pharmacological therapies and contributes to ongoing
myocardial ischemia, hypotension, or HF. (Level of
Evidence: C)
3. Cardioversion is recommended for patients with AF or
atrial ﬂutter and pre-excitation when tachycardia is associ-
ated with hemodynamic instability. (Level of Evidence: C)
CLASS IIa
1. It is reasonable to perform repeated cardioversions in pa-
tients with persistent AF, provided that sinus rhythm can be
maintained for a clinically meaningful period between car-
dioversion procedures. Severity of AF symptoms and patient
preference should be considered when embarking on a
strategy requiring serial cardioversion procedures. (Level of
Evidence: C)
5.3. Pharmacological Cardioversion
CLASS I
1. Flecainide, dofetilide, propafenone, and intravenous ibutilide
are useful for pharmacological cardioversion of AF or atrial
ﬂutter, provided contraindications to the selected drug are
absent (120–125). (Level of Evidence: A)
CLASS IIa
1. Administration of oral amiodarone is a reasonable option for
pharmacological cardioversion of AF (126,127). (Level of
Evidence: A)
TABLE 7
Dose Selection of Oral Anticoagulant Options for Patients With Nonvalvular AF and CKD
(Based on Prescribing Information for the United States)*
Renal Function Warfarin (92) Dabigatran† (74) Rivaroxaban† (75) Apixaban† (76)
Normal/mild impairment Dose adjusted for
INR 2.0–3.0
150 mg BID
(CrCl >30 mL/min)
20 mg QD with the evening meal
(CrCl >50 mL/min)
5.0 or 2.5 mg BID‡
Moderate impairment Dose adjusted for
INR 2.0–3.0
150 mg BID
(CrCl >30 mL/min)
15 mg QD with the evening meal
(CrCl 30–50 mL/min)
5.0 or 2.5 mg BID‡
Severe impairment Dose adjusted for
INR 2.0–3.0§
75 mg BIDk
(CrCl 15–30 mL/min)
15 mg QD with the evening meal
(CrCl 15–30 mL/min)
No recommendation.
See Section 4.2.2.2 in the full-text guideline¶
End-stage CKD not
on dialysis
Dose adjusted for
INR 2.0–3.0§
Not recommended¶
(CrCl <15 mL/min)
Not recommended¶
(CrCl <15 mL/min)
No recommendation.
See Section 4.2.2.2 in the full-text guideline¶
End-stage CKD on dialysis Dose adjusted for
INR 2.0–3.0§
Not recommended¶
(CrCl <15 mL/min)
Not recommended¶
(CrCl <15 mL/min)
No recommendation.
See Section 4.2.2.2 in the full-text guideline¶ #
*Renal function should be evaluated before initiation of direct thrombin or factor Xa inhibitors and should be reevaluated when clinically indicated and at least annually. CrCl should be
measured using the Cockcroft-Gault method.
†The concomitant use of P-glycoprotein inducers or inhibitors with dabigatran or the concomitant use of dual P-glycoprotein and strong CYP3A4 inducers or inhibitors with either
rivaroxaban or apixaban, particularly in the setting of CKD, may require dosing adjustment or avoidance of concomitant drug use (see the FDA drug label at http://www.accessdata.fda.
gov/drugsatfda_docs/label/2014/202155s002lbl.pdf, Section 8.6 in the full-text guideline).
‡Use apixaban 2.5 mg BID if any 2 patient characteristics are present: Cr $1.5 mg/dL, $80 y of age, body weight #60 kg (76). Apixaban is not recommended in patients with severe
hepatic impairment.
§Dose-adjusted warfarin has been used, but observational data on safety and efﬁcacy are conﬂicting.
kModeling studies suggest that dabigatran 75 mg BID might be safe for patients with CrCl 15–30 mL/min, but this has not been validated in a prospective cohort. Some countries
outside the United States use 110 mg BID (74).
¶No published studies support a dose for this level of renal function.
#In patients with end-stage CKD on stable hemodialysis, prescribing information indicates the use of apixaban 5 mg BID with dose reduction to 2.5 mg BID if the patient is$80 y of age
or body weight is #60 kg.
AF indicates atrial ﬁbrillation; BID, twice daily; CKD, chronic kidney disease; Cr, creatinine; CrCl, creatinine clearance; FDA, Food and Drug Administration; INR, international
normalized ratio; and QD, once daily.
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22572. Propafenone or ﬂecainide (“pill-in-the-pocket”) in addition
to a beta blocker or nondihydropyridine calcium channel
antagonist is reasonable to terminate AF outside the hospital
once this treatment has been observed to be safe in a
monitored setting for selected patients (120). (Level of
Evidence: B)TABLE 8 Summary of Recommendations for Rate Control
Recommendations
Control ventricular rate using a beta blocker or nondihydropyridine calcium channel a
paroxysmal, persistent, or permanent AF
IV beta blocker or nondihydropyridine calcium channel blocker is recommended to sl
heart rate in the acute setting in patients without pre-excitation. In hemodynamic
patients, electrical cardioversion is indicated
For AF, assess heart rate control during exertion, adjusting pharmacological treatmen
A heart rate control (resting heart rate <80 bpm) strategy is reasonable for symptom
management of AF
IV amiodarone can be useful for rate control in critically ill patients without pre-excit
AV nodal ablation with permanent ventricular pacing is reasonable when pharmacolo
is inadequate and rhythm control is not achievable
A lenient rate-control strategy (resting heart rate <110 bpm) may be reasonable whe
remain asymptomatic and LV systolic function is preserved
Oral amiodarone may be useful for ventricular rate control when other measures are
or contraindicated
AV nodal ablation should not be performed without prior attempts to achieve rate co
with medications
Nondihydropyridine calcium channel antagonists should not be used in decompensat
With pre-excitation and AF, digoxin, nondihydropyridine calcium channel antagonists
amiodarone should not be administered
Dronedarone should not be used to control ventricular rate with permanent AF
AF indicates atrial ﬁbrillation; AV, atrioventricular; bpm, beats per minute; COR, Class of Rec
ventricular; and N/A, not applicable.CLASS III: HARM
1. Dofetilide therapy should not be initiated out of hospital
because of the risk of excessive QT prolongation that
can cause torsades de pointes (124,128). (Level of
Evidence: B)COR LOE References
ntagonist for I B (93–95)
ow ventricular
ally unstable
I B (96–99)
t as necessary I C N/A
atic IIa B (95,100)
ation IIa B (101–103)
gical therapy IIa B (104–106)
n patients IIb B (100)
unsuccessful IIb C N/A
ntrol III: Harm C N/A
ed HF III: Harm C N/A
, or III: Harm B (107)
III: Harm B (108,109)
ommendation; HF, heart failure; IV, intravenous; LOE, Level of Evidence; LV, left
TABLE 9 Common Medication Dosage for Rate Control of AF
Intravenous Administration Usual Oral Maintenance Dose
Beta blockers
Metoprolol tartrate 2.5–5.0 mg IV bolus over 2 min; up to 3 doses 25–100 mg BID
Metoprolol XL (succinate) N/A 50–400 mg QD
Atenolol N/A 25–100 mg QD
Esmolol 500 mcg/kg IV bolus over 1 min, then 50–300 mcg/kg/min IV N/A
Propranolol 1 mg IV over 1 min, up to 3 doses at 2-min intervals 10–40 mg TID or QID
Nadolol N/A 10–240 mg QD
Carvedilol N/A 3.125–25 mg BID
Bisoprolol N/A 2.5–10 mg QD
Nondihydropyridine calcium channel antagonists
Verapamil 0.0750.15 mg/kg IV bolus over 2 min; may give an additional 10.0 mg
after 30 min if no response, then 0.005 mg/kg/min infusion
180–480 mg QD (ER)
Diltiazem 0.25 mg/kg IV bolus over 2 min, then 515 mg/h 120–360 mg QD (ER)
Digitalis glycosides
Digoxin 0.25 mg IV with repeat dosing to a maximum of 1.5 mg over 24 h 0.125–0.25 mg QD
Others
Amiodarone* 300 mg IV over 1 h, then 10–50 mg/h over 24 h 100–200 mg QD
*Multiple dosing schemes exist for the use of amiodarone.
AF indicates atrial ﬁbrillation; BID, twice daily; ER, extended release; IV, intravenous; N/A, not applicable; QD, once daily; QID, 4 times a day; and TID, 3 times a day.
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22585.4. Antiarrhythmic Drugs to Maintain Sinus Rhythm
Table 11 summarizes the range of antiarrhythmic drugs
useful in the maintenance of sinus rhythm along with
toxicity proﬁles.
CLASS I
1. Before initiating antiarrhythmic drug therapy, treatment of
precipitating or reversible causes of AF is recommended.
(Level of Evidence: C)
2. The following antiarrhythmic drugs are recommended in
patients with AF to maintain sinus rhythm, depending on
underlying heart disease and comorbidities (Level of
Evidence: A):
a. Amiodarone (129–132)
b. Dofetilide (124,128)
c. Dronedarone (133–135)
d. Flecainide (130,136)
e. Propafenone (130,137–140)
f. Sotalol (130,138,141)
3. The risks of the antiarrhythmic drug, including proar-
rhythmia, should be considered before initiating therapy
with each drug. (Level of Evidence: C)
4. Because of its potential toxicities, amiodarone should only
be used after consideration of risks and when other agents
have failed or are contraindicated (129,137,142–145). (Level
of Evidence: C)CLASS IIa
1. A rhythm-control strategy with pharmacological
therapy can be useful in patients with AF for the treat-
ment of tachycardia-induced cardiomyopathy. (Level of
Evidence: C)
CLASS IIb
1. It may be reasonable to continue current antiarrhythmic drug
therapy in the setting of infrequent, well-tolerated re-
currences of AF when the drug has reduced the frequency or
symptoms of AF. (Level of Evidence: C)
CLASS III: HARM
1. Antiarrhythmic drugs for rhythm control should not be
continued when AF becomes permanent (Level of Evidence:
C), including dronedarone (108). (Level of Evidence: B)
2. Dronedarone should not be used for treatment of AF in pa-
tients with New York Heart Association class III and IV HF or
patients who have had an episode of decompensated HF in
the past 4 weeks (109). (Level of Evidence: B)5.5. Upstream Therapy
CLASS IIa
1. An angiotensin-converting enzyme (ACE) inhibitor or
angiotensin-receptor blocker (ARB) is reasonable for primary
prevention of new-onset AF in patients with HF with re-
duced left ventricular ejection fraction (147–149). (Level of
Evidence: B)
TABLE 10 Summary of Recommendations for Electrical and Pharmacological Cardioversion of AF and Atrial Flutter
Recommendations COR LOE References
Prevention of thromboembolism
With AF or atrial ﬂutter for $48 h, or unknown duration, anticoagulate with warfarin for at least 3 wk
before and 4 wk after cardioversion
I B (110–113)
With AF or atrial ﬂutter for >48 h or unknown duration, requiring immediate cardioversion,
anticoagulate as soon as possible and continue for at least 4 wk
I C N/A
With AF or atrial ﬂutter <48 h and high stroke risk, IV heparin or LMWH, or factor Xa or
direct thrombin inhibitor, is recommended before or immediately after cardioversion,
followed by long-term anticoagulation
I C N/A
Following cardioversion of AF, long-term anticoagulation should be based on thromboembolic risk I C N/A
With AF or atrial ﬂutter for $48 h or unknown duration and no anticoagulation for preceding 3 wk, it is
reasonable to perform TEE before cardioversion and then cardiovert if no LA thrombus is identiﬁed,
provided anticoagulation is achieved before TEE and maintained after cardioversion for at least 4 wk
IIa B (114)
With AF or atrial ﬂutter $48 h or unknown duration, anticoagulation with dabigatran, rivaroxaban, or
apixaban is reasonable for $3 wk before and 4 wk after cardioversion
IIa C (115–117)
With AF or atrial ﬂutter <48 h and low thromboembolic risk, IV heparin, LMWH, a new oral
anticoagulant, or no antithrombotic may be considered for cardioversion
IIb C (118)
Direct-current cardioversion
Cardioversion is recommended for AF or atrial ﬂutter to restore sinus rhythm. If unsuccessful,
cardioversion attempts may be repeated.
I B (119)
Cardioversion is recommended for AF or atrial ﬂutter with RVR, that does not respond to
pharmacological therapies
I C N/A
Cardioversion is recommended for AF or atrial ﬂutter and pre-excitation with hemodynamic instability I C N/A
It is reasonable to repeat cardioversion in persistent AF when sinus rhythm can be maintained for a
clinically meaningful time period between procedures
IIa C N/A
Pharmacological cardioversion
Flecainide, dofetilide, propafenone, and IV ibutilide are useful for cardioversion of AF or atrial ﬂutter,
provided contraindications to the selected drug are absent
I A (120–125)
Amiodarone is reasonable for pharmacological cardioversion of AF IIa A (126,127)
Propafenone or ﬂecainide (“pill-in-the-pocket”) to terminate AF out of hospital is reasonable once
observed to be safe in a monitored setting
IIa B (120)
Dofetilide should not be initiated out of hospital III: Harm B (124,128)
AF indicates atrial ﬁbrillation; COR, Class of Recommendation; IV, intravenous; LA, left atrial; LMWH, low-molecular-weight heparin; LOE, Level of Evidence; N/A, not applicable; RVR,
rapid ventricular response; and TEE, transesophageal echocardiography.
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1. Therapy with an ACE inhibitor or ARB may be considered for
primary prevention of new-onset AF in the setting of hy-
pertension (150). (Level of Evidence: B)
2. Statin therapy may be reasonable for primary prevention of
new-onset AF after coronary artery surgery (151,152). (Level
of Evidence: A)
CLASS III: NO BENEFIT
1. Therapy with an ACE inhibitor, ARB, or statin is not beneﬁcial
for primary prevention of AF in patients without cardiovas-
cular disease (153). (Level of Evidence: B)
5.6. AF Catheter Ablation to Maintain Sinus Rhythm
Figure 2 shows an approach to the integration of antiar-
rhythmic drugs and catheter ablation of AF in patients
without and with structural heart disease.
CLASS I
1. AF catheter ablation is useful for symptomatic paroxysmal
AF refractory or intolerant to at least 1 class I or IIIantiarrhythmic medication when a rhythm-control strategy
is desired (154–160). (Level of Evidence: A)
2. Before consideration of AF catheter ablation, assessment of
the procedural risks and outcomes relevant to the individual
patient is recommended. (Level of Evidence: C)
CLASS IIa
1. AF catheter ablation is reasonable for some patients with
symptomatic persistent AF refractory or intolerant to at
least 1 class I or III antiarrhythmic medication (157,161–163).
(Level of Evidence: A)
2. In patients with recurrent symptomatic paroxysmal
AF, catheter ablation is a reasonable initial rhythm-control
strategy before therapeutic trials of antiarrhythmic drug
therapy, after weighing the risks and outcomes of drug and
ablation therapy (164–166). (Level of Evidence: B)
CLASS IIb
1. AF catheter ablation may be considered for symptomatic
long-standing (>12 months) persistent AF refractory or in-
tolerant to at least 1 class I or III antiarrhythmic medication
TABLE 11 Dosage and Safety Considerations for Maintenance of Sinus Rhythm in AF
Drug Usual Doses Exclude/Use With Caution
Major Pharmacokinetic
Drug Interactions
Vaughan Williams class IA
Disopyramide  Immediate release:
100–200 mg once every 6 h
 Extended release: 200–400 mg
once every 12 h
 HF
 Prolonged QT interval
 Prostatism, glaucoma
 Avoid other QT interval
prolonging drugs
 Metabolized by CYP3A4: caution with inhibitors
(e.g., verapamil, diltiazem, ketoconazole,
macrolide antibiotics, protease inhibitors,
grapefruit juice) and inducers (e.g., rifampin,
phenobarbital, phenytoin)
Quinidine  324–648 mg every 8 h  Prolonged QT interval
 Diarrhea
 Inhibits CYP2D6: [concentrations of tricyclic
antidepressants, metoprolol, antipsychotics;
Yefﬁcacy of codeine
 Inhibits P-glycoprotein: [digoxin concentration
Vaughan Williams class IC
Flecainide  50–200 mg once every 12 h  Sinus or AV node dysfunction
 HF
 CAD
 Atrial ﬂutter
 Infranodal conduction disease
 Brugada syndrome
 Renal or liver disease
 Metabolized by CYP2D6 (inhibitors include
quinidine, ﬂuoxetine, tricyclics; also genetically
absent in 7%–10% of population) and renal
excretion (dual impairment can [[plasma
concentration)
Propafenone  Immediate release: 150–300 mg
once every 8 h
 Extended release: 225–425 mg
once every 12 h
 Sinus or AV node dysfunction
 HF
 CAD
 Atrial ﬂutter
 Infranodal conduction disease
 Brugada syndrome
 Liver disease
 Asthma
 Metabolized by CYP2D6 (inhibitors include
quinidine, ﬂuoxetine, tricyclics; also genetically
absent in 7%–10% of population)—poor
metabolizers have [beta blockade
 Inhibits P-glycoprotein: [digoxin concentration
 Inhibits CYP2C9: [warfarin concentration
([INR 25%)
Vaughan Williams class III
Amiodarone  Oral: 400–600 mg daily in divided
doses for 2–4 wk; maintenance
typically 100200 mg QD
 IV: 150 mg over 10 min; then
1 mg/min for 6 h; then 0.5 mg/min
for 18 h or change to oral dosing;
after 24 h, consider decreasing
dose to 0.25 mg/min
 Sinus or AV node dysfunction
 Infranodal conduction disease
 Lung disease
 Prolonged QT interval
 Inhibits most CYPs to cause drug interaction:
[concentrations of warfarin ([INR 0%–200%),
statins, many other drugs
 Inhibits P-glycoprotein: [digoxin concentration
Dofetilide  125–500 mcg once every 12 h  Prolonged QT interval
 Renal disease
 Hypokalemia
 Hypomagnesemia
 Diuretic therapy
 Avoid other QT interval
prolonging drugs
 Primary renal elimination involving glomerular
ﬁltration and active tubular secretion: verapamil,
HCTZ, cimetidine, ketoconazole, trimethoprim,
prochlorperazine, and megestrol are contraindicated;
discontinue amiodarone at least 3 mo before
initiation
Dronedarone  400 mg once every 12 h  Bradycardia
 HF
 Long-standing persistent
AF/ﬂutter
 Liver disease
 Prolonged QT interval
 Metabolized by CYP3A: caution with inhibitors
(e.g., verapamil, diltiazem, ketoconazole,
macrolide antibiotics, protease inhibitors,
grapefruit juice) and inducers (e.g., rifampin,
phenobarbital, phenytoin)
 Inhibits CYP3A, CYP2D6, P-glycoprotein:
[concentrations of some statins, sirolimus,
tacrolimus, beta blockers, digoxin
Sotalol  40–160 mg once every 12 h  Prolonged QT interval
 Renal disease
 Hypokalemia
 Hypomagnesemia
 Diuretic therapy
 Avoid other QT interval
prolonging drugs
 Sinus or AV nodal dysfunction
 HF
 Asthma
 None (renal excretion)
AF indicates atrial ﬁbrillation; AV, atrioventricular; CAD, coronary artery disease; HCTZ, hydrochlorothiazide; HF, heart failure; INR, international normalized ratio; IV, intravenous; and
QD, once daily.
Adapted with permission from Roden et al. (146).
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2261when a rhythm-control strategy is desired (154,167). (Level of
Evidence: B)
2. AF catheter ablation may be considered before initiation
of antiarrhythmic drug therapy with a class I or III anti-
arrhythmic medication for symptomatic persistent AF
when a rhythm-control strategy is desired. (Level of
Evidence: C)
CLASS III: HARM
1. AF catheter ablation should not be performed in patients
who cannot be treated with anticoagulant therapy during
and after the procedure. (Level of Evidence: C)
2. AF catheter ablation to restore sinus rhythm should not be
performed with the sole intent of obviating the need for
anticoagulation. (Level of Evidence: C)
5.7. Surgical Maze Procedures
CLASS IIa
1. An AF surgical ablation procedure is reasonable for selected
patients with AF undergoing cardiac surgery for other in-
dications. (Level of Evidence: C)
CLASS IIb
1. A stand-alone AF surgical ablation procedure may be
reasonable for selected patients with highly symptomatic AFFIGURE 2 Strategies for rhythm control in patients with paroxysmal* and p
*Catheter ablation is only recommended as ﬁrst-line therapy for patients with p
†Drugs are listed alphabetically.
‡Depending on patient preference when performed in experienced centers.
§Not recommended with severe LVH (wall thickness >1.5 cm).
kShould be used with caution in patients at risk for torsades de pointes ventricu
¶Should be combined with AV nodal blocking agents.
AF indicates atrial ﬁbrillation; AV, atrioventricular; CAD, coronary artery diseasenot well managed with other approaches (168). (Level of
Evidence: B)6. SPECIFIC PATIENT GROUPS AND AF:
RECOMMENDATIONS
See Table 12 for a summary of recommendations for this
section.
6.1. Hypertrophic Cardiomyopathy
CLASS I
1. Anticoagulation is indicated in patients with hypertrophic
cardiomyopathy (HCM) with AF independent of the
CHA2DS2-VASc score (169,170). (Level of Evidence: B)
CLASS IIa
1. Antiarrhythmic medications can be useful to prevent recur-
rent AF in patients with HCM. Amiodarone or disopyramide
combined with a beta blocker or nondihydropyridine calcium
channel antagonists are reasonable for therapy. (Level of
Evidence: C)
2. AF catheter ablation can be beneﬁcial in patients with HCM
in whom a rhythm-control strategy is desired when antiar-
rhythmic drugs fail or are not tolerated (171–174). (Level of
Evidence: B)ersistent AF.†
aroxysmal AF (Class IIa recommendation).
lar tachycardia.
; HF, heart failure; and LVH, left ventricular hypertrophy.
TABLE 12 Summary of Recommendations for Speciﬁc Patient Groups and AF
Recommendations COR LOE References
Hypertrophic cardiomyopathy
Anticoagulation is indicated in HCM with AF independent of the CHA2DS2-VASc score I B (169,170)
Antiarrhythmic drugs can be useful to prevent recurrent AF in HCM. Amiodarone or disopyramide
combined with a beta blocker or nondihydropyridine calcium channel antagonist are reasonable
IIa C N/A
AF catheter ablation can be beneﬁcial for HCM to facilitate a rhythm-control strategy when
antiarrhythmics fail or are not tolerated
IIa B (171–174)
Sotalol, dofetilide, and dronedarone may be considered for a rhythm-control strategy in HCM IIb C (12)
AF complicating ACS
Urgent cardioversion of new-onset AF in the setting of ACS is recommended for patients with
hemodynamic compromise, ongoing ischemia, or inadequate rate control
I C N/A
IV beta blockers are recommended to slow RVR with ACS and no HF, hemodynamic instability,
or bronchospasm
I C N/A
With ACS and AF with CHA2DS2-VASc score $2, anticoagulation with warfarin is recommended
unless contraindicated
I C N/A
Amiodarone or digoxin may be considered to slow RVR with ACS and AF and severe LV dysfunction
and HF or hemodynamic instability
IIb C N/A
Nondihydropyridine calcium antagonists might be considered to slow RVR with ACS and AF only in
the absence of signiﬁcant HF or hemodynamic instability
IIb C N/A
Hyperthyroidism
Beta blockers are recommended to control ventricular rate with AF complicating thyrotoxicosis
unless contraindicated
I C N/A
When beta blockers cannot be used, a nondihydropyridine calcium channel antagonist is
recommended to control ventricular rate
I C N/A
Pulmonary diseases
A nondihydropyridine calcium channel antagonist is recommended to control ventricular rate
with AF and COPD
I C N/A
Cardioversion should be attempted for patients with pulmonary disease who become
hemodynamically unstable with new-onset AF
I C N/A
WPW and pre-excitation syndromes
Cardioversion is recommended for patients with AF, WPW syndrome, and RVR who are
hemodynamically compromised
I C (175)
IV procainamide or ibutilide to restore sinus rhythm or slow ventricular rate is recommended for
patients with pre-excited AF and RVR who are not hemodynamically compromised
I C (175)
Catheter ablation of the accessory pathway is recommended in symptomatic patients with
pre-excited AF, especially if the accessory pathway has a short refractory period
I C (175)
IV amiodarone, adenosine, digoxin, or nondihydropyridine calcium channel antagonists in patients
with WPW syndrome who have pre-excited AF is potentially harmful
III: Harm B (176–178)
Heart failure
A beta blocker or nondihydropyridine calcium channel antagonist is recommended for persistent
or permanent AF in patients with HFpEF
I B (95)
In the absence of preexcitation, an IV beta blocker (or a nondihydropyridine calcium channel
antagonist with HFpEF) is recommended to slow ventricular response to AF in the acute
setting, with caution in patients with overt congestion, hypotension, or HFrEF
I B (179–182)
In the absence of pre-excitation, IV digoxin or amiodarone is recommended to control
heart rate acutely
I B (103,180,183,184)
Assess heart rate during exercise and adjust pharmacological treatment in symptomatic
patients during activity
I C N/A
Digoxin is effective to control resting heart rate with HFrEF I C N/A
A combination of digoxin and beta blocker (or a nondihydropyridine calcium channel antagonist
with HFpEF) is reasonable to control resting and exercise heart rate with AF
IIa B (93,180)
It is reasonable to perform AV node ablation with ventricular pacing to control heart rate when
pharmacological therapy is insufﬁcient or not tolerated
IIa B (95,185,186)
IV amiodarone can be useful to control heart rate with AF when other measures are unsuccessful
or contraindicated
IIa C N/A
With AF and RVR causing or suspected of causing tachycardia-induced cardiomyopathy, it is
reasonable to achieve rate control by AV nodal blockade or a rhythm-control strategy
IIa B (187–189)
Continued on the next page
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TABLE 12 Continued
Recommendations COR LOE References
In patients with chronic HF who remain symptomatic from AF despite a rate-control strategy, it is
reasonable to use a rhythm-control strategy
IIa C N/A
Amiodarone may be considered when resting and exercise heart rate cannot be controlled with a beta blocker
(or a nondihydropyridine calcium channel antagonist with HFpEF) or digoxin, alone or in combination
IIb C N/A
AV node ablation may be considered when rate cannot be controlled and tachycardia-mediated
cardiomyopathy is suspected
IIb C N/A
AV node ablation should not be performed without a pharmacological trial to control ventricular rate III: Harm C N/A
For rate control, IV nondihydropyridine calcium channel antagonists, IV beta blockers,
and dronedarone should not be given with decompensated HF
III: Harm C N/A
Familial (genetic) AF
For patients with AF and multigenerational family members with AF, referral to a tertiary
care center for genetic counseling and testing may be considered
IIb C N/A
Postoperative cardiac and thoracic surgery
A beta blocker is recommended to treat postoperative AF unless contraindicated I A (190–193)
A nondihydropyridine calcium channel blocker is recommended when a beta blocker is inadequate to
achieve rate control with postoperative AF
I B (194)
Preoperative amiodarone reduces AF with cardiac surgery and is reasonable as prophylactic therapy
for patients at high risk of postoperative AF
IIa A (195–197)
It is reasonable to restore sinus rhythm pharmacologically with ibutilide or direct-current
cardioversion with postoperative AF
IIa B (198)
It is reasonable to administer antiarrhythmic medications to maintain sinus rhythm with recurrent or
refractory postoperative AF
IIa B (194)
It is reasonable to administer antithrombotic medications for postoperative AF IIa B (199)
It is reasonable to manage new-onset postoperative AF with rate control and anticoagulation
with cardioversion if AF does not revert spontaneously to sinus rhythm during follow-up
IIa C N/A
Prophylactic sotalol may be considered for patients with AF risk after cardiac surgery IIb B (193,200)
Colchicine may be considered postoperatively to reduce AF after cardiac surgery IIb B (201)
ACS indicates acute coronary syndromes; AF, atrial ﬁbrillation; AV, atrioventricular; CHA2DS2-VASc, Congestive heart failure, Hypertension, Age$75 years (doubled), Diabetes mellitus,
Prior Stroke or TIA or thromboembolism (doubled), Vascular disease, Age 65 to 74 years, Sex category; COPD, chronic obstructive pulmonary disease; COR, Class of Recommendation;
HCM, hypertrophic cardiomyopathy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; IV, intravenous; LOE,
Level of Evidence; LV, left ventricular; N/A, not applicable; RVR, rapid ventricular response; and WPW, Wolff-Parkinson-White.
J A C C V O L . 6 4 , N O . 2 1 , 2 0 1 4 January et al.
D E C E M B E R 2 , 2 0 1 4 : 2 2 4 6 – 8 0 Executive Summary: AHA/ACC/HRS Atrial Fibrillation Guideline
2263CLASS IIb
1. Sotalol, dofetilide, and dronedarone may be considered for a
rhythm-control strategy in patients with HCM (12). (Level of
Evidence: C)6.2. AF Complicating Acute Coronary Syndromes
CLASS I
1. Urgent direct-current cardioversion of new-onset AF in the
setting of acute coronary syndromes (ACS) is recom-
mended for patients with hemodynamic compromise,
ongoing ischemia, or inadequate rate control. (Level of
Evidence: C)
2. Intravenous beta blockers are recommended to slow a rapid
ventricular response to AF in patients with ACS who do not
display HF, hemodynamic instability, or bronchospasm.
(Level of Evidence: C)
3. For patients with ACS and AF with a CHA2DS2-VASc score of
2 or greater, anticoagulation with warfarin is recommended
unless contraindicated. (Level of Evidence: C)CLASS IIb
1. Administration of amiodarone or digoxin may be consid-
ered to slow a rapid ventricular response in patients with
ACS and AF associated with severe left ventricular
dysfunction and HF or hemodynamic instability. (Level of
Evidence: C)
2. Administration of nondihydropyridine calcium antagonists
might be considered to slow a rapid ventricular response in
patients with ACS and AF only in the absence of signiﬁcant
HF or hemodynamic instability. (Level of Evidence: C)6.3. Hyperthyroidism
CLASS I
1. Beta blockers are recommended to control ventricular rate in
patients with AF complicating thyrotoxicosis unless contra-
indicated. (Level of Evidence: C)
2. In circumstances in which a beta blocker cannot be used,
a nondihydropyridine calcium channel antagonist is recom-
mended to control the ventricular rate. (Level of Evidence: C)
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CLASS I
1. A nondihydropyridine calcium channel antagonist is recom-
mended to control the ventricular rate in patients with
AF and chronic obstructive pulmonary disease. (Level of
Evidence: C)
2. Direct-current cardioversion should be attempted in patients
with pulmonary disease who become hemodynamically
unstable as a consequence of new-onset AF. (Level of
Evidence: C)
6.5. Wolff-Parkinson-White and Pre-Excitation Syndromes
CLASS I
1. Prompt direct-current cardioversion is recommended for
patients with AF, Wolff-Parkinson-White syndrome, and
rapid ventricular response who are hemodynamically
compromised (175). (Level of Evidence: C)
2. Intravenous procainamide or ibutilide to restore sinus
rhythm or slow the ventricular rate is recommended for
patients with pre-excited AF and rapid ventricular response
who are not hemodynamically compromised (175). (Level of
Evidence: C)
3. Catheter ablation of the accessory pathway is recommended
in symptomatic patients with pre-excited AF, especially
if the accessory pathway has a short refractory period
that allows rapid antegrade conduction (175). (Level of
Evidence: C)
CLASS III: HARM
1. Administration of intravenous amiodarone, adenosine,
digoxin (oral or intravenous), or nondihydropyridine calcium
channel antagonists (oral or intravenous) in patients with
Wolff-Parkinson-White syndrome who have pre-excited AF is
potentially harmful because these drugs accelerate the
ventricular rate (176–178). (Level of Evidence: B)6.6. Heart Failure
CLASS I
1. Control of resting heart rate using either a beta blocker or
nondihydropyridine calcium channel antagonist is recom-
mended for patients with persistent or permanent AF and
compensated HF with preserved ejection fraction (HFpEF)
(95). (Level of Evidence: B)
2. In the absence of pre-excitation, intravenous beta-blocker
administration (or a nondihydropyridine calcium channel
antagonist in patients with HFpEF) is recommended to slow
the ventricular response to AF in the acute setting, with
caution needed in patients with overt congestion, hypo-
tension, or HF with reduced left ventricular ejection fraction
(179–182). (Level of Evidence: B)
3. In the absence of pre-excitation, intravenous digoxin or
amiodarone is recommended to control heart rate acutely
in patients with HF (103,180,183,184). (Level of Evidence: B)4. Assessment of heart rate control during exercise and
adjustment of pharmacological treatment to keep the rate in
the physiological range is useful in symptomatic patients
during activity. (Level of Evidence: C)
5. Digoxin is effective to control resting heart rate in
patients with HF with reduced ejection fraction. (Level of
Evidence: C)
CLASS IIa
1. A combination of digoxin and a beta blocker (or a non-
dihydropyridine calcium channel antagonist for patients with
HFpEF) is reasonable to control resting and exercise heart
rate in patients with AF (93,180). (Level of Evidence: B)
2. It is reasonable to perform AV node ablation with ventricular
pacing to control heart rate when pharmacological therapy
is insufﬁcient or not tolerated (95,185,186). (Level of
Evidence: B)
3. Intravenous amiodarone can be useful to control heart rate
in patients with AF when other measures are unsuccessful
or contraindicated. (Level of Evidence: C)
4. For patients with AF and rapid ventricular response causing
or suspected of causing tachycardia-induced cardiomyopa-
thy, it is reasonable to achieve rate control by either AV
nodal blockade or a rhythm-control strategy (187–189).
(Level of Evidence: B)
5. For patients with chronic HF who remain symptomatic from
AF despite a rate-control strategy, it is reasonable to use a
rhythm-control strategy. (Level of Evidence: C)
CLASS IIb
1. Oral amiodarone may be considered when resting and exer-
cise heart rate cannot be adequately controlled using a beta
blocker (or a nondihydropyridine calcium channel antagonist
in patients with HFpEF) or digoxin, alone or in combination.
(Level of Evidence: C)
2. AV node ablation may be considered when the rate cannot
be controlled and tachycardia-mediated cardiomyopathy is
suspected. (Level of Evidence: C)
CLASS III: HARM
1. AV node ablation should not be performed without a phar-
macological trial to achieve ventricular rate control. (Level
of Evidence: C)
2. For rate control, intravenous nondihydropyridine calcium
channel antagonists, intravenous beta blockers, and drone-
darone should not be administered to patients with de-
compensated HF. (Level of Evidence: C)
6.7. Familial (Genetic) AF
CLASS IIb
1. For patients with AF and multigenerational family members
with AF, referral to a tertiary care center for genetic coun-
seling and testing may be considered. (Level of Evidence: C)
J A C C V O L . 6 4 , N O . 2 1 , 2 0 1 4 January et al.
D E C E M B E R 2 , 2 0 1 4 : 2 2 4 6 – 8 0 Executive Summary: AHA/ACC/HRS Atrial Fibrillation Guideline
22656.8. Postoperative Cardiac and Thoracic Surgery
CLASS I
1. Treating patients who develop AF after cardiac surgery
with a beta blocker is recommended unless contraindicated
(190–193). (Level of Evidence: A)
2. A nondihydropyridine calcium channel blocker is recom-
mended when a beta blocker is inadequate to achieve rate
control in patients with postoperative AF (194). (Level of
Evidence: B)
CLASS IIa
1. Preoperative administration of amiodarone reduces the
incidence of AF in patients undergoing cardiac surgery
and is reasonable as prophylactic therapy for patients
at high risk for postoperative AF (195–197). (Level of
Evidence: A)
2. It is reasonable to restore sinus rhythm pharmacologically
with ibutilide or direct-current cardioversion in patients
who develop postoperative AF, as advised for nonsurgical
patients (198). (Level of Evidence: B)
3. It is reasonable to administer antiarrhythmic medications
in an attempt to maintain sinus rhythm in patients
with recurrent or refractory postoperative AF, as advised
for other patients who develop AF (194). (Level of
Evidence: B)
4. It is reasonable to administer antithrombotic medication in
patients who develop postoperative AF, as advised for
nonsurgical patients (199). (Level of Evidence: B)
5. It is reasonable to manage well-tolerated, new-onset post-
operative AF with rate control and anticoagulation with
cardioversion if AF does not revert spontaneously to sinus
rhythm during follow-up. (Level of Evidence: C)
CLASS IIb
1. Prophylactic administration of sotalol may be considered for
patients at risk of developing AF after cardiac surgery
(193,200). (Level of Evidence: B)
2. Administration of colchicine may be considered for patients
postoperatively to reduce AF after cardiac surgery (201).
(Level of Evidence: B)
7. EVIDENCE GAPS AND
FUTURE RESEARCH DIRECTIONS
The past decade has seen substantial progress in the
understanding of mechanisms of AF, clinical imple-
mentation of ablation for maintaining sinus rhythm,
and new drugs for stroke prevention. Further studies
are needed to better inform clinicians about the risks
and beneﬁts of therapeutic options for an individual
patient. Continued research is needed into the mecha-
nisms that initiate and sustain AF. It is hoped thatbetter understanding of these tissue and cellular
mechanisms will lead to more deﬁned approaches to
treating and abolishing AF. This includes new method-
ological approaches for AF ablation that would favor-
ably impact survival, thromboembolism, and quality of
life across different patient proﬁles. New pharmacolog-
ical therapies are needed, including antiarrhythmic
drugs that have atrial selectivity and drugs that target
ﬁbrosis, which will hopefully reach clinical evaluation.
The successful introduction of new anticoagulants is
encouraging, and further investigations will better
inform clinical practices for optimizing beneﬁcial ap-
plications and minimizing the risks of these agents,
particularly in the elderly, in the presence of comor-
bidities and in the periprocedural period. Further in-
vestigations must be performed to better understand
the links between the presence of AF, AF burden, and
stroke risk, and to better deﬁne the relationship be-
tween AF and dementia. The roles of emerging surgical
and procedural therapies to reduce stroke will be
deﬁned. Great promise lies in prevention. Future stra-
tegies for reversing the growing epidemic of AF will
come from basic science and genetic, epidemiological,
and clinical studies.PRESIDENTS AND STAFF
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2280APPENDIX 3. INITIAL CLINICAL EVALUATION IN PATIENTS WITH AFMinimum Evaluation1. History and physical examination,
to deﬁne
 Presence and nature of symptoms associated with AF
 Clinical type of AF (paroxysmal, persistent, or permanent)
 Onset of ﬁrst symptomatic attack or date of discovery of AF
 Frequency, duration, precipitating factors, and modes of initiation or termination of AF
 Response to any pharmacological agents that have been administered
 Presence of any underlying heart disease or reversible conditions (e.g., hyperthyroidism or alcohol consumption)
2. ECG, to identify  Rhythm (verify AF)
 LVH
 P-wave duration and morphology or ﬁbrillatory waves
 Pre-excitation
 Bundle-branch block
 Prior MI
 Other atrial arrhythmias
 To measure and follow R-R, QRS, and QT intervals in conjunction with antiarrhythmic drug therapy
3. TTE, to identify  VHD
 LA and RA size
 LV and RV size and function
 Peak RV pressure (pulmonary hypertension)
 LV hypertrophy
 LA thrombus (low sensitivity)
 Pericardial disease
4. Blood tests of thyroid, renal, and
hepatic function
 For a ﬁrst episode of AF
 When ventricular rate is difﬁcult to control
Additional Testing (1 or several tests may be necessary)
1. 6-min walk test  If adequacy of rate control is in question
 If adequacy of rate control is in question
2. Exercise testing  To reproduce exercise-induced AF
 To exclude ischemia before treatment of selected patients with a type IC * antiarrhythmic drug
3. Holter or event monitoring  If diagnosis of type of arrhythmia is in question
 As a means of evaluating rate control
4. TEE  To identify LA thrombus (in LAA)
 To guide cardioversion
5. Electrophysiological study  To clarify the mechanism of wide-QRS-complex tachycardia
 To identify a predisposing arrhythmia such as atrial ﬂutter or paroxysmal supraventricular tachycardia
 To seek sites for curative AF ablation or AV conduction block/modiﬁcation
6. Chest radiograph, to evaluate  Lung parenchyma, when clinical ﬁndings suggest an abnormality
 Pulmonary vasculature, when clinical ﬁndings suggest an abnormality
*Type IC refers to the Vaughan Williams classiﬁcation of antiarrhythmic drugs.
AF indicates atrial ﬁbrillation; AV, atrioventricular; ECG, electrocardiogram; LA, left atrial; LAA, left atrial appendage; LV, left ventricular; LVH, left ventricular hypertrophy; MI,
myocardial infarction; RA, right atrial; RV, right ventricular; TEE, transesophageal echocardiography; TTE, transthoracic echocardiogram; and VHD, valvular heart disease.
Adapted with permission from Fuster et al. (5)
